These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy. Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659 [TBL] [Abstract][Full Text] [Related]
5. Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study. Lemonne N; Möckesch B; Charlot K; Garnier Y; Waltz X; Lamarre Y; Antoine-Jonville S; Etienne-Julan M; Hardy-Dessources MD; Romana M; Connes P Clin Hemorheol Microcirc; 2017; 67(2):141-148. PubMed ID: 28759962 [TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148 [TBL] [Abstract][Full Text] [Related]
7. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264 [TBL] [Abstract][Full Text] [Related]
8. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302 [TBL] [Abstract][Full Text] [Related]
9. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy. Borba R; Lima CS; Grotto HZ J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630 [TBL] [Abstract][Full Text] [Related]
10. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115 [TBL] [Abstract][Full Text] [Related]
11. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil. Silva-Pinto AC; Angulo IL; Brunetta DM; Neves FI; Bassi SC; Santis GC; Covas DT Sao Paulo Med J; 2013; 131(4):238-43. PubMed ID: 24141294 [TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Charache S Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197 [TBL] [Abstract][Full Text] [Related]
13. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Orringer EP; Blythe DS; Johnson AE; Phillips G; Dover GJ; Parker JC Blood; 1991 Jul; 78(1):212-6. PubMed ID: 1712641 [TBL] [Abstract][Full Text] [Related]
14. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia. Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591 [TBL] [Abstract][Full Text] [Related]
15. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Conran N; Oresco-Santos C; Acosta HC; Fattori A; Saad ST; Costa FF Br J Haematol; 2004 Feb; 124(4):547-54. PubMed ID: 14984506 [TBL] [Abstract][Full Text] [Related]
16. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Saleh AW; Hillen HF; Duits AJ Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885 [TBL] [Abstract][Full Text] [Related]
17. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582 [TBL] [Abstract][Full Text] [Related]
18. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628 [TBL] [Abstract][Full Text] [Related]
19. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia. Ballas SK; Connes P; Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261 [TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia. Lemonne N; Charlot K; Waltz X; Ballas SK; Lamarre Y; Lee K; Hierso R; Connes C; Etienne-Julan M; Romana M; Connes P Haematologica; 2015 Oct; 100(10):e383-6. PubMed ID: 26137960 [No Abstract] [Full Text] [Related] [Next] [New Search]